摘要
以聚（乳酸-羟基乙酸）共聚物（PLGA）为载体制备盐酸多柔比星缓释植入剂,测定植入剂的释放度和PLGA失重率,结果表明PLGA体外降解曲线呈＂S＂形,起初的迟缓期后降解速率加快,5周时失重率达80%。植入剂表现出趋于零级的药物释放模式（r=0.9880）,在0~25 d日均释放度达3.26%,35 d时累积释放度达90%以上。植入剂可持续释药1个月,释药速率主要取决于PLGA降解速率,通过调节PLGA降解速率可以很好地控制药物的释放度。
The implants were prepared by incorporating doxorubicin hydrochloride into poly（lactide-co-glycolide）（PLGA） matrix.The drug release rate and content of implants were determined by HPLC,and the weight loss of PLGA was also tested.The result showed that in vitro degradation curve of PLGA appeared to be like ＇S＇.The degradation rate of PLGA was enhanced followed by an initial lag time,and the weight loss of PLGA was 80% for 5 weeks.The implants provided zero-order drug release at a rate of 3.26% per day for 25 days（r=0.9880）.The cumulative release rate of the implant was more than 90% at 35 days.The drug release from the implants has sustained for 1 month.The drug release rate of the implant depends predominantly on the degradation rate of PLGA.This release is well controlled by regulating the degradation rate of PLGA matrix.
出处
《生物医学工程研究》
2011年第3期167-169,共3页
Journal Of Biomedical Engineering Research
基金
山东省科技发展计划资助项目(2005GG3202053)
关键词
盐酸多柔比星
聚(乳酸-羟基乙酸)
缓释植入剂
体外释药
体外降解
Doxorubicin hydrochloride
Poly（lactide-co-glycolide）
Sustained-release implant
In vitro drug release
In vitro degradation
